LATEST NEWS: Roche MS drug Ocrevus approved by FDA after three-month delay - (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues.
LATEST NEWS: FDA silence on generic Advair may be good news for GSK - LONDON (Reuters) - GlaxoSmithKline shares gained on Wednesday as lack of news about U.S. approval of a generic copy of its blockbuster inhaled lung drug Advair buoyed speculation that a threat to profits might be delayed.
LATEST NEWS: Brain implant lets paralyzed man feed himself using his thoughts - CHICAGO (Reuters) - A paralyzed man in Cleveland fed himself mashed potatoes for the first time in eight years, aided by a computer-brain interface that reads his thoughts and sends signals to move muscles in his arm, U.S. researchers said on Tuesday.
LATEST NEWS: Trump tells lawmakers he expects deal 'very quickly' on healthcare - WASHINGTON (Reuters) - U.S. President Donald Trump told a group of senators on Tuesday that he expected lawmakers would be able to reach a deal on healthcare, without offering specifics on how they would do it or what had changed since a healthcare reform bill was pulled last week for insufficient support.
LATEST NEWS: U.S. senator launches probe into five top opioid drugmakers - (Reuters) - U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation's top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country's deadly opioid crisis.
LATEST NEWS: Vertex cystic fibrosis combination succeeds in late-stage trials - (Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy.
LATEST NEWS: FDA approves Regeneron, Sanofi $37,000 per year eczema drug - (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.